[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"liver-cirrhosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:liver-cirrhosis":26},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,104,0,25,[9,44,70,108,137,170,209,238,271,302,325,357,384,411,430,451,482,504,525,551,578,603,626,647,674],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100652555","application-of-different-scores-in-predicting-outcomes-of-cirrhotic-patients-awaiting-liver-transplantation-100652555",false,"NCT07777705","Application of Different Scores in Predicting Outcomes of Cirrhotic Patients Awaiting Liver Transplantation","transplant","Inclusion Criteria:\n\n* • All patients with liver cirrhosis (whatever the etiology) eligible for liver transplantation above the age of 18.\n\n  * Written informed consent provided.\n\nExclusion Criteria:\n\n* Old age (above 60 years old)\n* Acute liver cell failure without underlying cirrhosis\n* Absolute contraindications (e.g., uncontrolled sepsis, severe cardiopulmonary dysfunction, active malignancy).\n* Extra-MELD indications (e.g., hepatopulmonary syndrome, refractory ascites, cholestatic pruritus, hepatoblastoma). We restricted our cohort to patients listed for liver transplantation based on MELD-driven indications. This decision was made to reduce heterogeneity and ensure that eligibility determinations were primarily driven by MELD scores, thereby allowing us to isolate the relative contribution of frailty in the context of MELD-based allocation","ALL","18 Years","60 Years",{"count":21,"type":22},153,"ESTIMATED","OBSERVATIONAL","the goal of this observational study is to apply different scores 1. To assess Fatigue, Frailty, Liver Transplant Comorbidity Index and MELD 3.0 in patients with liver cirrhosis awaiting liver transplantation.\n\n2\\. To evaluate the predictive accuracy of these Scores for the short-term outcomes (early complications, recurrent hospitalization and 3-month mortality). 3. To determine whether using these Scores in the pre-transplant evaluation improves risk stratification compared to MELD score alone.",[26,27],"Liver Cirrhosis","Liver Transplant",[29,30,31],"cirrhosis and transplantation","Liver cirrhosis","Liver transplantation","NOT_YET_RECRUITING","2026-08-19",{"date":35,"type":36},"2026-08-20","ACTUAL",{"date":38,"type":22},"2026-09-01",{"date":40,"type":22},"2028-01-01",{"name":42,"class":43},"Assiut University","OTHER",{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100617969","phase-2-a-study-to-test-whether-bi-3802876-is-tolerated-in-people-with-compensated-liver-cirrhosis-due-to-metabolic-dysfunction--associated-steatohepatitis-mash-100617969","NCT07325526","A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)","A Phase IIa Double-blind, Placebo-controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 3802876 in Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis (MASH)","Inclusion Criteria:\n\n* Male or female adults ≥18 to ≤75 years of age at the time of screening, and at least the legal age of consent in countries where it is \\> 18 years\n* Patients meeting criteria for Child-Pugh category A without history of previous decompensation event\n* Compensated Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis diagnosed by 1 of the following:\n\n  * The most recent liver biopsy (≤ 5 years prior to randomisation) showing cirrhosis with steatohepatitis. There is no evidence for a competing aetiology.\n  * Historical biopsy (≤ 5 years prior to randomisation) showed steatohepatitis with F1 to F3 fibrosis, but now with cirrhosis either by NITs or biopsy. There is no evidence of competing aetiology. If there is a current biopsy (≤ 6 months prior to randomisation), and it does not show evidence of steatosis or steatohepatitis, there is at least 1 coexisting or history of metabolic comorbidity.\n  * The most recent liver biopsy (≤ 5 years prior to randomisation) showing cirrhosis with steatosis. There are at least 2 coexisting metabolic comorbidities or history of metabolic comorbidities, including obesity and\u002For type 2 diabetes mellitus (T2DM). There is no evidence for a competing aetiology.\n  * Historical biopsy (≤ 5 years prior to randomisation) showed steatosis, but now with cirrhosis, either by NITs or biopsy. If there is a current biopsy (≤ 6 months prior to randomisation), and it does not show evidence of steatosis or steatohepatitis, there are at least 2 coexisting or history of metabolic comorbidities including obesity and\u002For T2DM. There is no evidence of competing aetiology.\n  * Trial participant with cirrhosis with current or previous imaging showing evidence of steatosis (by liver ultrasound or CT scan or FibroScan® with CAP ≥288 dB\u002Fm or MRI-PDFF ≥5%). There is no liver histology available. There are at least 2 coexisting or history of metabolic comorbidities, including obesity and\u002For T2DM. There is no evidence of competing aetiology.\n  * Cryptogenic cirrhosis' (either by NITs or biopsy; not to exceed 20% of trial participants) without current or previous evidence of steatosis by imaging or steatosis\u002Fsteatohepatitis by histology. There are at least 2 coexisting or history of metabolic comorbidities, including obesity and\u002For T2DM. There is no evidence of competing aetiology.\n\nFurther inclusion criteria apply.\n\nExclusion Criteria:\n\n* Patients with clinically significant signs of advanced portal hypertension defined by any of the following:\n\n  * VCTE ≥30 kPa\n  * VCTE ≥25 kPa if the platelets are ≥150,000\u002FμL\n  * History of esophageal or gastric varices (Grade ≥1) on endoscopy\n  * Hepatic venous pressure gradient (HVPG) ≥10 mmHg\n* Other causes of liver disease based on medical history and\u002For centralized review of liver histology, including but not limited to alcoholic liver disease, autoimmune disorders (e.g., primary biliary cholangitis \\[PBC\\], primary sclerosing cholangitis \\[PSC\\], autoimmune hepatitis), drug-induced hepatotoxicity, Wilson disease, clinically significant iron overload, or alpha-1- antitryspin deficiency\n* Chronic viral hepatitis parameters that would be considered exclusionary for the participation in this trial are (hepatitis B and C testing will be done at screening visit):\n\n  * Hepatitis B virus (HBV): Past or present hepatitis B infection, including a positive hepatitis B surface antigen (HBsAg) and\u002For detectable HBV Deoxyribonucleic Acid (DNA).\n  * Hepatitis C virus (HCV): Past or present hepatitis C infection, including positive hepatitis C antibodies and\u002For detectable HCV ribonucleic acid (RNA).\n* History of liver transplantation or patients listed for liver transplantation\n* Suspicion, confirmed diagnosis, or history of Hepatocellular Carcinoma (HCC)\n* Present or past evidence of decompensating events of liver cirrhosis\n* Model for End-Stage Liver Disease (MELD) score \\> 12, unless due to therapeutic anti-coagulation\n* History of significant alcohol consumption (defined as intake of \\> 210 g\u002Fweek in males and \\> 140 g\u002Fweek in females on average over a consecutive period of more than 3 months) within 1 year prior to screening\n* International Normalized Ratio (INR) \\>1.3 unless due to therapeutic anticoagulants or laboratory error Further exclusion criteria apply.","75 Years",{"count":53,"type":22},29,"INTERVENTIONAL",[56],"PHASE2","This study is open to adults with a type of confirmed liver condition called compensated cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH). The purpose of this study is to find out how well a study medicine called BI 3802876 is tolerated in people with this condition. The study looks at how different doses of BI 3802876 are handled by the body. BI 3802876 is being developed to improve liver health in people living with this liver condition.\n\nParticipants are put in 3 different dose groups randomly, which means by chance. Participants within a group get BI 3802876 or placebo. Placebo looks like BI 3802876 but does not contain any medicine. Participants have more than twice the chance of receiving BI 3802876 than placebo. The study medicine is given as an infusion into a vein.\n\nParticipants are in the study for about half a year. During this time, they visit the study site 12 times. At 2 visits, participants get the study medicine. Doctors collect information on any health problems and take blood samples to check how BI 3802876 is handled by the body. They compare results between the groups.",[26],"RECRUITING","2026-08-18",{"date":33,"type":36},{"date":63,"type":36},"2026-02-27",{"date":65,"type":22},"2027-08-05",{"name":67,"class":68},"Boehringer Ingelheim","INDUSTRY",27,{"id":71,"slug":72,"hasResults":12,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":54,"phases":79,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":100,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100429619","phase-1-direct-oral-anticoagulants-rivaroxaban-and-apixaban-in-patients-with-liver-cirrhosis-100429619","NCT04874428","Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis","Pharmacokinetics and Pharmacodynamics of Single Doses of Rivaroxaban and Apixaban in Patients With Compensated Liver Cirrhosis","Inclusion Criteria:\n\n* Age 18 years or older\n* Patient with previously diagnosed liver cirrhosis (Child-Pugh score grade A and B).\n* Written informed consent\n\nExclusion Criteria:\n\n* Positive pregnancy test (only for women in childbearing age with intact uterus), pregnancy or nursing women\n* Intake of prophylactic or therapeutic oral anticoagulant (phenprocoumon, acenocoumarol, dabigatran etc.) 2 weeks prior to inclusion in the study\n* Application of parenteral anticoagulant, e.g. unfractionated heparin, low molecular weight heparins, heparin derivatives (fondaparinux etc.) 1 week prior to inclusion in the study\n* Pharmacologic platelet inhibition within 2 weeks prior to inclusion in the study\n* Known coagulation disorders (e.g. von Willebrand's disease, hemophilia)\n* Active, clinically significant bleeding\n* Congenital or acquired bleeding disorder\n* High risk of bleeding (e.g. active ulcerative gastrointestinal disease)\n* Uncontrolled severe hypertension\n* Vascular retinopathy\n* Acute infection\n* Acute bacterial endocarditis\n* Severe anemia (haemoglobin ≤100 g\u002FL)\n* Hereditary galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption\n* Severe liver dysfunction (Child-Pugh Score grade C)\n* Hepatic encephalopathy ≥ grade 3\n* Severe renal impairment with a creatinine clearance (GFR) of \\\u003C30 ml\u002Fmin\n* Known intolerance to the study medications rivaroxaban and\u002For apixaban\n* Concomitant treatment with a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, lopinavir, ritonavir, indinavir).\n* Concomitant treatment with a P-glycoprotein inhibitor and a weak or moderate CYP3A4 inhibitor (e.g., erythromycin, azithromycin, diltiazem, verapamil, quinidine, ranolazine, dronedarone, amiodarone, felodipine).\n* Concomitant treatment with a P-glycoprotein inducer and a strong CYP3A4 inducer (e.g., carbamazepine, phenytoin, rifampicin).\n* Wash-out period of less than two weeks prior to the application of study drug in case of prior treatment with a strong CYP3A4 inhibitor or a P-glycoprotein inhibitor and weak or moderate CYP3A4 inhibitor or with a P-glycoprotein inducer or strong CYP3A4 inducer.",{"count":78,"type":22},24,[80],"PHASE1","The aim of this study is to investigate the pharmacokinetic and pharmacodynamic parameters of rivaroxaban and apixaban in patients with compensated liver cirrhosis (Child-Pugh class A and B).\n\nThe enrolled participants receive a prophylactic single oral dose of either rivaroxaban (10 mg) or apixaban (2.5 mg) at around 8 a.m. on the day of the trial. Blood samples are taken 0.5 hours pre-dose and 1, 2, 3, 4, 6, 8, 12 hours post-dose.\n\nA follow-up telephone call is performed 5 days after the study intervention to collect safety data.",[26],[84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,26,99],"Rivaroxaban","Apixaban","Factor Xa Inhibitors","Antithrombins","Serine Proteinase Inhibitors","Protease Inhibitors","Enzyme Inhibitors","Anticoagulants","Pharmacokinetics","Pharmacodynamics","Thromboembolism","Venous Thromboembolism","Embolism and Thrombosis","Vascular Diseases","Cardiovascular Diseases","Liver Diseases",{"date":33,"type":36},{"date":102,"type":36},"2021-05-19",{"date":104,"type":22},"2026-12",{"name":106,"class":43},"Insel Gruppe AG, University Hospital Bern",1,{"id":109,"slug":110,"hasResults":12,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":54,"phases":118,"briefSummary":120,"conditions":121,"keywords":122,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":107},"100612347","terlipressin-vs-somatostatin-in-cirrhotic-patients-with-acute-gastrointestinal-bleeding-and-acute-kidney-injury-100612347","NCT07252401","Terlipressin vs. Somatostatin in Cirrhotic Patients With Acute Upper Gastrointestinal Bleeding and Renal Dysfunction","Terlipressin vs. Somatostatin in Cirrhotic Patients With Acute Upper Gastrointestinal Bleeding and Renal Dysfunction: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* patients have a definite diagnosis of live cirrhosis and AUGIB;\n* patients present with renal dysfunction at admission;\n* patients' age 18-70 years old;\n* patients or relatives can sign the informed consent form.\n\nExclusion Criteria:\n\n* patients have hepatorenal syndrome- acute renal injury (HRS-AKI);\n* patients have structural kidney injury;\n* patients have chronic kidney disease;\n* patients received kidney replacement therapy before enrollment;\n* patients have a history of liver transplantation or TIPS;\n* patients have acute liver failure or acute-on-chronic liver failure;\n* patients have hepatic or renal malignant tumor;\n* patients have severe diseases of the heart, lungs, and brain;\n* patients have contraindications for experimental drugs;\n* patients are in pregnancy or lactation;\n* patients participated in other clinical studies within 3 months before enrollment;\n* patients have other conditions that investigators deem unsuitable for enrollment in the study.","70 Years",{"count":117,"type":22},64,[119],"NA","Acute upper gastrointestinal bleeding (AUGIB) is a common complication in the decompensated stage of liver cirrhosis, of which approximately 70% is acute variceal bleeding (AVB) caused by portal hypertension. Existing evidence suggests that both terlipressin and somatostatin can be used to control AUGIB in cirrhotic patients, but terlipressin may be the first-line treatment for cirrhotic patients with AUGIB complicated by renal dysfunction (RD). Herein, a multicenter randomized controlled trial (RCT) has been designed to compare the efficacy of terlipressin and somatostatin in the treatment of cirrhotic patients with AUGIB complicated by RD.",[26],[123,124,125,126,127,128],"terlipressin","somatostatin","liver cirrhosis","acute upper gastrointestinal bleeding","renal dysfunction","acute kidney injury","2026-08-14",{"date":60,"type":36},{"date":132,"type":22},"2026-09-25",{"date":134,"type":22},"2028-03-31",{"name":136,"class":43},"General Hospital of Shenyang Military Region",{"id":138,"slug":139,"hasResults":12,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":146,"conditions":147,"keywords":154,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":169},"100598351","digital-early-warning-system-for-acute-lung-injury-in-liver-surgery-100598351","NCT07070362","Digital Early Warning System for Acute Lung Injury in Liver Surgery","The Construction of a Digital Intelligence Early Warning System for the Whole Process of Acute Lung Injury in Liver Surgery Based on Cardiopulmonary Interaction Characteristics","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Undergoing major liver surgery (including two-segment or more hepatectomy, liver transplantation, etc.)\n* Voluntary participation with signed informed consent",{"count":145,"type":22},3000,"This study aims to develop an explainable machine learning model that takes into account the characteristics of cardiopulmonary interactions. This model will enable early prediction of acute lung injury (ALI) in patients undergoing major liver surgery. The research will create a digital early-warning system for ALI, thereby supporting clinical diagnosis and treatment decisions. This, in turn, should help reduce the incidence and mortality rates associated with ALI.",[148,26,149,150,151,152,153],"Acute Lung Injury(ALI)","ARDS, Human","MASLD","MASLD\u002FMASH (Metabolic Dysfunction-Associated Steatotic Liver Disease \u002F Metabolic Dysfunction-Associated Steatohepatitis)","NAFLD (Nonalcoholic Fatty Liver Disease)","Liver Cancer, Adult",[155,156,157,158,159],"Digital Intelligence","Acute Lung Injury","PPCs","Liver Surgery","Cardiopulmonary Interaction;","2026-08-13",{"date":162,"type":36},"2026-08-17",{"date":164,"type":36},"2024-11-01",{"date":166,"type":22},"2027-11-30",{"name":168,"class":43},"Beijing Tsinghua Chang Gung Hospital",4,{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":178,"targetDuration":180,"studyType":23,"phases":4,"briefSummary":181,"conditions":182,"keywords":187,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":4},"100651885","prospective-evaluation-of-hepatocellular-carcinoma-surveillance-in-at-risk-patients-screening-hcc-100651885","NCT07764835","Prospective Evaluation of Hepatocellular Carcinoma Surveillance in At-Risk Patients (Screening HCC)","Prospective Evaluation of Hepatocellular Carcinoma Surveillance in At-Risk Patients Using Semiannual Ultrasound LI-RADS and Alpha-Fetoprotein: A Multicenter Real-World Observational Study","Screening HCC","Inclusion Criteria:\n\n* Written informed consent.\n* Age 18 years or older.\n* Liver cirrhosis of any etiology.\n* Chronic hepatitis B with moderate or high risk of HCC according to PAGE-B criteria.\n* Non-cirrhotic chronic liver disease with increased risk for HCC, including fibrosis stage 3 or higher or metabolic dysfunction-associated steatotic liver disease (MASLD) with one or more risk factors for HCC.\n* Followed at hepatology clinics within the Rede D'Or health network.\n* Eligible for routine HCC surveillance with ultrasound and alpha-fetoprotein according to standard clinical practice.\n\nExclusion Criteria:\n\n* Known hepatocellular carcinoma at enrollment.\n* Previous diagnosis of hepatocellular carcinoma.\n* Metastatic liver disease.\n* Other malignant liver tumors present at enrollment.\n* Clinical condition preventing routine surveillance follow-up.\n* Inability to provide informed consent.",{"count":179,"type":22},300,"36 Months","This prospective multicenter observational study evaluates the performance of a structured hepatocellular carcinoma (HCC) surveillance program in patients at increased risk of developing liver cancer. Participants will undergo routine surveillance with semiannual abdominal ultrasound reported using the Ultrasound Liver Imaging Reporting and Data System (US LI-RADS) and serum alpha-fetoprotein (AFP) testing as part of standard clinical care. The study aims to assess HCC detection rates, stage at diagnosis, detection of other hepatic malignancies, and the time intervals between detection, diagnosis, and treatment in a real-world setting. Approximately 300 participants will be enrolled and followed for up to 36 months.",[183,26,184,185,186],"Hepatocellular Carcinoma","Chronic Hepatitis B","Metabolic Dysfunction-Associated Steatotic Liver Disease","Advanced Liver Fibrosis",[188,183,189,190,191,192,193,194,26,184,150,185,195,196,197,198,199,200],"HCC","Liver Cancer","HCC Surveillance","US LI-RADS","Ultrasound LI-RADS","Alpha-Fetoprotein","AFP","Real-World Study","Observational Study","Early Detection","BCLC","Rede D'Or","Brazil","2026-08-10",{"date":129,"type":36},{"date":204,"type":22},"2026-09-15",{"date":206,"type":22},"2029-06-30",{"name":208,"class":43},"D'Or Institute for Research and Education",{"id":210,"slug":211,"hasResults":12,"nctId":212,"briefTitle":213,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":216,"enrollmentInfo":217,"targetDuration":4,"studyType":54,"phases":219,"briefSummary":221,"conditions":222,"keywords":225,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":237},"100522562","phase-4-national-liver-cancer-screening-trial-100522562","NCT06084234","National Liver Cancer Screening Trial","TRACER","Inclusion Criteria:\n\nPatient must meet all of the following inclusion criteria:\n\n1. Adult patients ages 18-85 with cirrhosis from any etiology or with chronic hepatitis B with a PAGE-B score greater than 9 within 12 months of enrollment\n2. Patient is eligible for HCC surveillance according to treating physician or by the site investigator\n3. Able to provide informed consent\n4. Life expectancy \\>6 months (after consent) as determined by the treating provider or site investigator\n\nExclusion Criteria:\n\nPatient will be excluded for any of the following exclusion criteria:\n\n1. Child Pugh C cirrhosis\n2. History or clinical symptoms of hepatocellular carcinoma or cholangiocarcinoma\n3. History of solid nodule on baseline ultrasound (i.e., lesion 1cm or greater) within 9 months prior to consent without subsequent diagnostic CT\u002FMRI demonstrating benign nature)\n4. AFP \\>20 ng\u002FmL within 6 months prior to consent, in the absence of a contrast-enhanced CT or MRI within 6 months of AFP (before or after) level demonstrating lack of suspicious liver lesions\n5. Newly diagnosed LR-3 greater than or equal to 1 cm within 6 months prior to consent\n6. History of LR-4, LR-5, or LR-M on multi-phase CT or contrast-enhanced MRI within 6 months prior to consent\n7. Presence of another active cancer besides non-melanomatous skin cancer or indolent cancer under active surveillance (e.g., prostate cancer or renal cell carcinoma) within the 2 years prior to consent\n8. Patient's provider is planning to use MRI- or CT- based surveillance moving forward\n9. History of a transjugular intrahepatic portosystemic shunt (TIPS)\n10. History of Fontan associated liver disease or cardiac cirrhosis\n11. History of solid organ transplantation\n12. Actively listed for liver transplantation\n13. Diagnosis of alcohol-associated hepatitis within 3 months prior to consent\n14. Documented current or continued signs and symptoms of acute Wilson disease (acute liver failure, acute neurological deficits, hemolysis)\n15. In patients with primary sclerosing cholangitis (PSC): Current active cholangitis within 90 days prior to consent\n16. Known or documented habitual non-adherence to previous research studies or medical procedures or unwillingness to adhere to protocol (e.g., unwilling to obtain consent or samples)\n17. In patients living with HIV: CD4+ T cell count less than 100 cells\u002Fmm3 within 60 days prior to consent\n18. Known pregnancy at consent\n19. Active warfarin use","85 Years",{"count":218,"type":22},5500,[220],"PHASE4","The National Liver Cancer Screening Trial is an adaptive randomized phase IV Trial comparing ultrasound-based versus biomarker-based screening in 5500 patients with cirrhosis from any etiology or patients with chronic hepatitis B infection. Eligible patients will be randomized in a 1:1 fashion to Arm A using semi-annual ultrasound and AFP-based screening or Arm B using semi-annual screening using GALAD alone. Randomization will be stratified by sex, enrolling site, Child Pugh class (A vs. B), and HCC etiology (viral vs. non-viral). Patients will be recruited from 15 sites (mix of tertiary care and large community health systems) over a 3-year period, and the primary endpoint of the phase IV trial, reduction in late-stage HCC, will be assessed after 5.5 years.",[223,189,26,224],"Carcinoma, Hepatocellular","Hepatitis B",[226,227,228],"Hepatocellular carcinoma surveillance","GALAD","Alpha Fetoprotein",{"date":230,"type":36},"2026-08-12",{"date":232,"type":36},"2023-12-26",{"date":234,"type":22},"2034-12-31",{"name":236,"class":43},"University of Texas Southwestern Medical Center",19,{"id":239,"slug":240,"hasResults":12,"nctId":241,"briefTitle":242,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":245,"targetDuration":4,"studyType":54,"phases":247,"briefSummary":248,"conditions":249,"keywords":250,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":4},"100650615","predicting-response-and-exposure-changes-in-cirrhosis-for-effectiveness-100650615","NCT07750587","Predicting Response and Exposure Changes in Cirrhosis for Effectiveness","PRECISE","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Clinical, radiological and\u002For histological diagnosis of cirrhosis\n* Informed consent signed prior to participation in the study\n\nExclusion Criteria:\n\n* Original MELD score \\> 30\n* Estimated creatinine clearance \\\u003C 30 mL\u002Fmin, calculated by using the Cockcroft-Gault equation\n* Known poor metaboliser status for one of the CYP enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A) described in the medical record\n* Previous clinically relevant adverse reaction or intolerance to one of the drugs in the probe drug cocktail\n* Recent exposure to one of the drugs in the drug probe cocktail within five elimination half-lives prior to drug administration (corresponding to approximately 1-10 days depending on the probe drug)36-40:\n\n  * caffeine: 5h x 5 = 25 hours\n  * warfarin: 50h x 5 = 250 hours\n  * esomeprazole: 1.3h x 5 = 6.5 hours\n  * metoprolol: 3.5h x 5 = 17.5 hours\n  * midazolam: 2.5h x 5 = 12.5 hours\n* Absolute contraindication for one of the drugs in the probe drug cocktail36-40:\n\n  * caffeine: drug hypersensitivity\n  * warfarin: drug hypersensitivity and active bleeding\n  * esomeprazole: drug hypersensitivity, congenital long QT syndrome and suspected gastrointestinal malignancy\n  * metoprolol: drug hypersensitivity, cardiogenic shock, second- and third degree AV block, bradycardia (\\\u003C 50 beats per minute), sick sinus syndrome including SA block, symptomatic hypotension (mean arterial pressure \\\u003C 65 mmHg), metabolic acidosis and untreated pheochromocytoma\n  * midazolam: drug hypersensitivity, severe chronic obstructive pulmonary disease, myasthenia gravis, sleep apnoea syndrome requiring CPAP, Parkinson's disease, severe respiratory insufficiency or acute respiratory depression\n* Interactions with strong to moderate CYP inhibitors and inducers of the following P450 enzymes: CYP1A2 (inhibitors: ciprofloxacin, fluvoxamine), CYP2C9, CYP2C19, CYP2D6 (inhibitors: bupropion, cinacalcet, fluoxetine, quinidine, paroxetine, terbinafine) and CYP3A (inducers: apalutamide, carbamazepine, efavirenz, enzalutamide, phenobarbital, phenytoin, hypericum, lumacaftor, mitotane, nevirapine, primidone, rifabutin, rifampicin; inhibitors: clarithromycin, cobicistat, erythromycin, itraconazole, ketoconazole, posaconazole, ritonavir, voriconazole)41,42\n* Use of concomitant medication with a clinically relevant PK or PD interaction with one or more components of the probe drug cocktail, if the interaction is expected to affect PK endpoint interpretation or compromise participant safety and cannot be appropriately managed\n* Refusing or unable to give informed consent (e.g. hepatic encephalopathy)",{"count":246,"type":22},45,[119],"The goal of this clinical trial is to learn how liver cirrhosis affects the way the body processes drugs in adults with different stages of liver cirrhosis. This information may help improve drug dosing for people with liver cirrhosis in the future. The main question it aims to answer is:\n\n• How does the severity of liver cirrhosis affect the way the body processes a combination of five drugs, each used to measure the activity of a different liver enzyme?\n\nResearchers will compare participants with mild, moderate, and severe liver cirrhosis to see whether the processing of drugs differs between these groups.\n\nParticipants will:\n\n* Fast overnight for 8 hours before receiving the drugs\n* Have a scan to measure the stiffness of their liver and spleen\n* Receive a single low dose of five drugs: caffeine, warfarin, esomeprazole, metoprolol, and midazolam\n* Have blood samples taken before and at several times up to 72 hours after receiving the drugs, including samples for genetic testing and blood clotting checks\n* Avoid caffeine-containing food and drinks from 48 hours before receiving the drugs until the final blood sample",[26],[92,251,252,253,254,255,256,257,258,259,260,261],"Drug metabolism","Cytochrome P450","Probe-drug cocktail","Cirrhosis","Hepatic impairment","CYP1A2","CYP2C9","CYP2C19","CYP2D6","CYP3A","Precision dosing","2026-08-07",{"date":264,"type":36},"2026-08-11",{"date":266,"type":22},"2026-11-01",{"date":268,"type":22},"2028-12-01",{"name":270,"class":43},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":272,"slug":273,"hasResults":12,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":278,"targetDuration":4,"studyType":54,"phases":280,"briefSummary":281,"conditions":282,"keywords":285,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":301},"100650987","proximal-splenic-artery-embolization-psae-for-the-treatment-of-refractory-ascites-in-decompensated-cirrhosis-100650987","NCT07755059","Proximal Splenic Artery Embolization (PSAE) for the Treatment of Refractory Ascites in Decompensated Cirrhosis","A Prospective, Multi-Center, Single-Arm Clinical Study of Proximal Splenic Artery Embolization (PSAE) for the Treatment of Refractory Ascites in Decompensated Cirrhosis","Inclusion Criteria:\n\n* Age ≥ 18 years at the time of informed consent.\n* Decompensated cirrhosis confirmed by clinical, laboratory, radiographic, or histologic criteria.\n* Portal hypertension of sinusoidal origin. Pre-sinusoidal (e.g., idiopathic non-cirrhotic portal hypertension, schistosomiasis) and post-sinusoidal (e.g., Budd-Chiari syndrome, right-heart failure, constrictive pericarditis) etiologies are excluded.\n* Refractory or recurrent ascites defined as ascites not controlled by maximum tolerated diuretic therapy (spironolactone ≤ 400 mg\u002Fday + furosemide ≤ 160 mg\u002Fday, or maximum tolerated doses below these limits) and sodium restriction, or diuretic-intractable due to diuretic-induced complications.\n* Demonstrated large-volume paracentesis (LVP) dependence for ≥ 3 consecutive months prior to screening, with ≥ 2 LVP sessions per month on average during that window, documented in the institutional medical record or in external paracentesis procedure records released to the investigator.\n* Ineligible or relatively contraindicated for TIPS. Acceptable reasons include but are not limited to: MELD-Na \\> 18 with additional risk factors, pre-existing or recurrent overt hepatic encephalopathy, advanced age with comorbidity, clinically significant cardiopulmonary disease, or anatomic contraindication.\n* Life expectancy ≥ 6 months in the judgment of the enrolling investigator.\n* Able and willing to provide written informed consent and to adhere to the study visit and assessment schedule.\n* Abdominal cross-sectional imaging (CT or MRI) within 60 days of enrollment confirming patency of the main portal vein and main splenic vein, and absence of findings that would contraindicate PSAE.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years.\n* Unable to provide informed consent and without an appropriate legally authorized representative.\n* Pre-sinusoidal or post-sinusoidal portal hypertension (e.g., extrahepatic portal vein thrombosis, idiopathic non-cirrhotic portal hypertension, schistosomiasis, Budd-Chiari syndrome, hepatic sinusoidal obstruction syndrome, constrictive pericarditis, right-heart failure).\n* Main portal vein thrombosis, splenic vein thrombosis, or superior mesenteric vein thrombosis on screening imaging.\n* Active listing for liver transplantation with MELD-Na ≥ 20 at screening, or any listing status in which transplantation within 6 months is judged highly likely by the site transplant team. (Listed participants with MELD-Na \\\u003C 20 and low anticipated short-term transplant probability may be enrolled with documented site transplant-team concurrence.)\n* Pre-existing splenectomy, prior distal splenic artery embolization, or pre-existing splenic abscess, large splenic infarction (≥ 30% of splenic parenchyma), or splenic mass on imaging.\n* Active or uncontrolled systemic infection, including spontaneous bacterial peritonitis in the prior 14 days, bacteremia in the prior 14 days, or any infection requiring parenteral antibiotics at the time of screening.\n* Active gastrointestinal bleeding within 14 days, or untreated high-risk esophageal or gastric varices (primary prophylaxis not yet established) - treatable prior to enrollment.\n* Severe coagulopathy not correctable to INR ≤ 2.0 and platelets ≥ 30 × 10⁹\u002FL on the day of the procedure.\n* Known severe allergy to iodinated contrast not manageable with standard pre-medication, or contrast contraindication precluding cross-sectional CT imaging.\n* eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m² not on renal replacement therapy, unless iodinated contrast use can be minimized per site protocol and nephrology concurrence is documented.\n* Pregnancy or breastfeeding. Participants of childbearing potential must have a negative serum pregnancy test at screening and agree to effective contraception through Month 6.\n* Hepatocellular carcinoma beyond BCLC Stage A, or any active extrahepatic malignancy with life expectancy \\\u003C 6 months.\n* Active substance use disorder other than alcohol or tobacco that, in the investigator's judgment, would preclude protocol adherence. Active alcohol use disorder is not exclusionary but is captured (AUDIT-C) and analyzed as a pre-specified covariate.\n* Enrollment in another interventional clinical trial within 30 days or concurrent with this study that could confound endpoints, including TIPS-related trials.\n* Any medical, psychiatric, or social condition that in the investigator's judgment would preclude safe participation or adherence to the protocol.",{"count":279,"type":22},60,[119],"The purpose of this study is to learn whether a procedure called Proximal Splenic Artery Embolization (PSAE) can lower the need for repeat fluid drainage in adults with cirrhosis and a buildup of fluid in the abdomen (ascites) that is no longer controlled by water pills and diet. Participants in this study have already been told that a standard procedure called Trans jugular Intrahepatic Portosystemic Shunt (TIPS) is not a safe option for them. The main objectives this study aims to answer are:\n\n* Does PSAE lower how often participants need paracentesis, the procedure used to drain fluid from the abdomen?\n* Does PSAE lower the total amount of fluid drained each month?\n* Does PSAE change the pressure inside the liver's veins and the blood flow in the liver and spleen?\n* Does PSAE improve day-to-day symptoms, quality of life, strength, and the ability to do usual activities?\n* What side effects or complications happen with PSAE in this group of people?\n\nParticipants will:\n\n* Undergo one PSAE procedure, during which small coils and\u002For plugs are placed in the artery that supplies the spleen to slow its blood flow\n* Have a pressure measurement taken in the liver's veins right before and right after the procedure, with a repeat measurement at 1 month\n* Attend follow-up visits at 1, 3, and 6 months that include blood tests, ultrasounds, symptoms and quality-of-life questionnaires, and a review of any paracentesis sessions since the last visit\n* Have a Computed Tomography (CT) scan or Magnetic Resonance Imaging (MRI) and an ultrasound of the liver and spleen blood vessels at the start of the study and again at 6 months",[283,26,284],"Ascites","Hypertension, Portal",[286,287,288,289,290,291,292],"Refractory Ascites","Decompensated Cirrhosis","Proximal Splenic Artery Embolization","Splenic Artery Embolization","Large Volume Paracentesis","Trans Jugular Intrahepatic Portosystemic Shunt","Hepatic Venous Pressure Gradient","2026-08-05",{"date":201,"type":36},{"date":296,"type":22},"2026-10-01",{"date":298,"type":22},"2030-10-01",{"name":300,"class":43},"Massachusetts General Hospital",3,{"id":303,"slug":304,"hasResults":12,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":308,"eligibilityCriteria":309,"healthyVolunteers":12,"sex":310,"minAge":18,"maxAge":311,"enrollmentInfo":312,"targetDuration":4,"studyType":54,"phases":313,"briefSummary":314,"conditions":315,"keywords":316,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":321,"completionDateStruct":322,"leadSponsor":323,"locationsCount":301},"100645405","phase-2-a-phase-2-study-of-foscenvivint-in-liver-cirrhosis-patients-caused-by-hivhcv-co-infection-with-hemophilia-100645405","NCT07681089","A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV\u002FHCV Co-infection With Hemophilia","A Multicenter, Single-Arm, Open-Label Phase 2 Study of Once-Weekly Foscenvivint in Patients With Liver Cirrhosis Due to HIV\u002FHCV Co-infection in the Setting of Hemophilia","OP-724-H202","Inclusion Criteria:\n\n* Patients with hemophilia and liver cirrhosis caused by HIV\u002FHCV co-infection who meet both of the following criteria:\n\n  1. Patients who are serum HIV-RNA positive or HIV antibody positive, with HIV-RNA maintained at \\\u003C200 copies\u002FmL and a CD4-positive T lymphocyte count of ≥200 cells\u002FµL at screening.\n  2. Patients with HCV infection who have achieved sustained virologic response (SVR) at least 12 months before registration.\n\n     * Patients with Child-Pugh class A or B liver cirrhosis (Child-Pugh score 5-9).\n     * Patients who meet at least one of the following criteria for the diagnosis of liver cirrhosis:\n\n  \u003C!-- -->\n\n  1. Liver stiffness measurement by FibroScan of ≥12.5 kPa, corresponding to fibrosis stage F4, at screening.\n  2. Abdominal CT showing changes in liver morphology and\u002For findings suggestive of portal hypertension.\n\n     * Patients with an Eastern Cooperative Oncology Group Performance Status of 0-2.\n\nExclusion Criteria:\n\n* Patients with liver cirrhosis caused by etiologies other than HCV or of unknown etiology.\n* Patients with esophageal or gastric varices judged by endoscopic examination at screening to require treatment.\n* Patients with current malignancy or a history of malignancy within 3 years before registration.\n* Patients who have undergone liver transplantation or other organ transplantation, including bone marrow transplantation.\n* Patients with active AIDS-defining disease requiring treatment. -","MALE","79 Years",{"count":169,"type":22},[56],"This is a phase 2 study to evaluate the efficacy and safety of foscenvivint in patients with liver cirrhosis resulting from HIV\u002FHCV co-infection in the setting of hemophilia.",[26],[26,317,318],"Hemophilia","HIV\u002FHCV co-infection","2026-08-03",{"date":293,"type":36},{"date":38,"type":22},{"date":134,"type":22},{"name":324,"class":43},"Kiminori Kimura, MD",{"id":326,"slug":327,"hasResults":12,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":331,"eligibilityCriteria":332,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":335,"conditions":336,"keywords":340,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":356},"100640555","establishing-a-reference-framework-for-outcomes-after-machine-preserved-liver-transplantation-in-europe-100640555","NCT07585890","Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe","Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe (REFRAME-MP)","REFRAME-MP","Inclusion Criteria:\n\n* All postmortal livers accepted (transplanted and not-transplanted after machine perfusion) upon organ offer for patients \\>18 years at the time of liver transplantation.\n* All donor types (DBD, DCD)\n* Preservation either with static cold storage alone or combined with machine perfusion (MP).\n* Donor livers underwent MP as part of routine clinical practice and the choice of perfusion protocol was made according to institutional standard practice.\n* Eligible MP protocols are:\n\n  1. end-ischemic single- or dual hypothermic oxygenated MP \\[e(D)HOPE\\],\n  2. end-ischemic (back-to-base) normothermic MP \\[eNMP\\],\n  3. continuous (device-to-donor) normothermic MP \\[cNMP\\],\n  4. e(D)HOPE followed by controlled oxygenated rewarming and normothermic MP \\[e(D)HOPE-COR-NMP)\\],\n  5. e(D)HOPE followed by normothermic MP \\[e(D)HOPE-NMP\\], or\n  6. Normothermic regional perfusion followed by SCS or an ex situ MP protocol.\n* A minimum follow-up of 12 months after liver transplantation is required.\n\nExclusion Criteria:\n\n* Livers that were allocated to a MP protocol as part of a prospective randomized or interventional clinical trial comparing different preservation techniques or any other invention.\n* Living donor liver transplantation",{"count":334,"type":22},10000,"Machine perfusion (MP) has become routine clinical practice in liver transplantation. However, as the field has matured, direct randomized comparisons between distinct MP modalities have become increasingly impractical, given that donor and graft characteristics often predetermine the optimal preservation strategy. Consequently, many studies continue to reference historical benchmark cohorts from the pre-perfusion era, or use risk scores developed before routine utilization of MP. These cohorts, while once valuable, fail to account for the paradigm shift that MP has introduced. Likewise, commonly used donor- and recipient-based risk scores were developed prior to the adoption of MP. While these scores aim to assess survival or morbidity after transplantation, none of them guide decisions about MP use or the most suitable perfusion protocol. As MP technologies continue to evolve there is a critical need for an updated reference framework that accurately reflects current clinical practice and captures the best achievable outcomes across all MP modalities.",[337,338,26,339],"End-stage Liver Disease (ESLD)","Acute Liver Failure","Liver Transplantation",[341,342,343,344,345,346,347],"machine perfusion","liver transplantation","hypothermic machine perfusion","normothermic machine perfusion","normothermic regional perfusion","organ preservation","machine preservation","2026-07-30",{"date":319,"type":36},{"date":351,"type":36},"2026-04-21",{"date":353,"type":22},"2030-12-31",{"name":355,"class":43},"University Medical Center Groningen",9,{"id":358,"slug":359,"hasResults":12,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":364,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":366,"conditions":367,"keywords":370,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":4},"100649292","evaluating-novel-scoring-systems-to-predict-outcomes-in-acute-on-chronic-liver-failure-100649292","NCT07734896","Evaluating Novel Scoring Systems to Predict Outcomes in Acute-on-Chronic Liver Failure","Evaluation of Novel Scores for Prediction of Outcomes in Patients With Acute-on-Chronic Liver Failure","Inclusion Criteria:\n\n* Patients aged 18 years or older.\n* Diagnosed with Acute-on-Chronic Liver Failure (ACLF) fulfilling the diagnostic criteria according to EASL-CLIF.\n* Admitted to the Intensive Care Unit (ICU) of the Tropical Medicine and Gastroenterology Department, Al-Rajhi University Hospital.\n\nExclusion Criteria:\n\n* Patients with hepatocellular carcinoma.\n* Patients with advanced extrahepatic malignancy.\n* Pregnant females.\n* Patients younger than 18 years old.\n* Patients with incomplete clinical or laboratory data.\n* Patients or first-degree relatives refusing participation.",{"count":365,"type":22},100,"Acute-on-chronic liver failure (ACLF) is a serious condition where a patient with long-term liver disease suddenly experiences severe liver worsening and failure of other organ systems, such as the kidneys or lungs. ACLF is associated with a high risk of short-term death, making early and accurate prediction of patient outcomes essential for guiding medical decisions.\n\nConventional scoring systems, such as the Child-Pugh and Model for End-Stage Liver Disease Sodium (MELD-Na) scores, are widely used to assess liver disease severity. However, these traditional models may not fully capture the intense systemic inflammation and multiorgan failure characteristic of ACLF. Recently, novel prognostic scoring models, specifically the CLIF-C ACLF-D score and the MELD-complication score, have been developed to better predict patient outcomes by integrating markers of inflammation, organ dysfunction, and clinical complications.\n\nThis study aims to evaluate and validate the clinical usefulness of these novel scoring models compared to conventional scores in predicting in-hospital and 28-day mortality among patients admitted with ACLF.\n\nParticipants enrolled in this prospective observational study will be recruited from the Intensive Care Unit (ICU) of the Tropical Medicine and Gastroenterology Department at Al-Rajhi University Hospital. Upon admission, participants will undergo routine clinical examinations, laboratory testing, and imaging. The various risk scores will be calculated at baseline. Participants will be monitored throughout their hospital stay, and their survival status will be followed for 28 days after admission to compare the accuracy of each scoring system.",[368,26,369],"Acute-on-Chronic Liver Failure (ACLF)","End Stage Liver Disease",[371,372,373,374,375],"CLIF-C ACLF-D Score","MELD-Complication Score","MELD-Na Score","Child-Pugh Score","Prognostic Scores","2026-07-25",{"date":378,"type":36},"2026-07-29",{"date":380,"type":22},"2026-08",{"date":382,"type":22},"2027-09",{"name":42,"class":43},{"id":385,"slug":386,"hasResults":12,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":390,"eligibilityCriteria":391,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":392,"targetDuration":4,"studyType":54,"phases":394,"briefSummary":396,"conditions":397,"keywords":398,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":4},"100648769","phase-3-apixaban-to-prevent-decompensation-of-early-liver-cirrhosis-trial-100648769","NCT07726693","Apixaban to Prevent Decompensation of Early Liver Cirrhosis Trial","Apixaban to Prevent dEcompensation of eArly Liver CirrHosis Trial","APEACH","Inclusion Criteria:\n\n1. Liver cirrhosis secondary to alcohol, with or without associated metabolic risk factors, i.e. Alcohol related liver disease (ARLD) or metabolic dysfunction-associated steatotic liver disease, where there has been a significant history of alcohol consumption (MetALD)\n2. Cirrhosis will be based on histology, or clear radiological evidence, e.g. nodular or heterogeneous liver or non-invasive testing (e.g. Fibroscan®, or Enhanced Liver Fibrosis (ELF) test\n3. Childs A Cirrhosis (Participants with a previous episode of decompensated cirrhosis who have now recompensated can be included)\n4. Participants with no hepatic encephalopathy or low-grade hepatic encephalopathy (Grade 0 or 1) taking lactulose and\u002For rifaximin\n5. Aged ≥18 years\n6. Clinical evidence of portal hypertension, defined as any 1 of:\n\n   * Evidence of abdominal collateral circulation, recanalised umbilical vein or varices on imaging\n   * Asymptomatic ascites (trace only) seen around the liver on imaging in patients who are not taking diuretics\n   * Liver stiffness measurement \\>20kPa on FibroScan®\u002F Vibration- Controlled Transient Elastography (VCTE) (where BMI \\\u003C35)\n   * Presence of Gastro-oesophageal varices at endoscopy\n   * Hepatic venous pressure gradient ≥ 10mmHg\n\nOr Platelet count \\\u003C 150,000 μL AND any 1 of:\n\n* Spleen size \\>13 cm in length\n* Liver stiffness measurement \\>20kPa on FibroScan®\u002FVCTE (where BMI \\>35)\n* Presence of portal hypertensive gastropathy at endoscopy\n\nExclusion Criteria:\n\n1. Evidence of decompensation (e.g. ascites requiring treatment other than a thin rim around liver on imaging, as above) (Evidence of decompensation as follows: Grade 2 or 3 Ascites, Grade 2 - 4 Hepatic Encephalopathy, Variceal Haemorrhage)\n2. Causes for cirrhosis other than alcohol, including those with MASLD who have never drunk alcohol above government recommended levels (14 units\u002Fweek)\n3. Pre-existing splanchnic vein thrombosis (portal, splenic, mesenteric, and hepatic veins)\n4. Use of (and need for) anticoagulation or dual antiplatelet therapy or clopidogrel\n5. Platelets \\\u003C50x109\u002FL at screening\n6. Moderate-severe renal impairment defined as eGFR \\\u003C30ml\u002Fmin at screening\n7. Recent variceal bleed or untreated large varices\n8. Malignancy in last 2 years if unlikely to survive trial because of comorbidity in the location PI's opinion\n9. Hepatocellular carcinoma\n10. Severe cardiac failure1 or Chronic Obstructive Pulmonary Disease (COPD)\n11. Pregnancy\n12. INR \\>1.7 (After vitamin K correction) at screening\n13. Previous hypersensitivity reaction to Apixaban",{"count":393,"type":22},1142,[395],"PHASE3","Liver disease is the only common cause of death that is increasing in numbers. Once people develop severe scarring (cirrhosis), there are no medications proven to help them live longer, healthier lives. Apixaban is already commonly used to prevent or treat blood clots and is known to be safe for those with cirrhosis.\n\nIn the early stages of cirrhosis, most people have no symptoms and lead normal lives; this is called \"compensated\" cirrhosis. However, when the liver stops working properly, they develop \"decompensated\" cirrhosis, which causes yellow skin, confusion, vomiting of blood and painful fluid build-up. This is serious, and people are extremely unwell with a poor quality of life, often need to go to the hospital and on average only live for 2 more years.\n\nThe APEACH trial will investigate whether giving compensated cirrhosis patients Apixaban will help stop them from developing decompensated cirrhosis and stay in good health for longer.\n\nPrevious research studies suggest that taking blood-thinning drugs is safe and helpful for cirrhosis. However, these did not have enough participants to be confident enough in the results to recommend use in everyday clinical care.\n\nThe APEACH trial will include enough participants to make it clear whether Apixaban is helpful or not.",[26],[26,399,400,85,401],"Alcohol Related Liver Disease (ARLD)","Metabolic dysfunction-associated steatotic liver disease","MetALD","2026-07-21",{"date":404,"type":36},"2026-07-24",{"date":406,"type":22},"2026-07-15",{"date":408,"type":22},"2031-03-30",{"name":410,"class":43},"University College, London",{"id":412,"slug":413,"hasResults":12,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":418,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":420,"conditions":421,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":426,"completionDateStruct":427,"leadSponsor":428,"locationsCount":4},"100647989","wearable-patch-ultrasound-probe-for-diagnosis-of-liver-stiffness-100647989","NCT07716384","Wearable Patch Ultrasound Probe for Diagnosis of Liver Stiffness","Diagnostic Accuracy of a Wearable Patch-Type Ultrasound Probe for Detecting Liver Fibrosis and Cirrhosis: A Prospective Cross-Sectional Study","Inclusion Criteria:\n\n* Confirmed or suspected chronic liver disease (including but not limited to chronic viral hepatitis, non-alcoholic fatty liver disease, and alcohol-related liver disease)\n* Scheduled to undergo, or have recently undergone, transient elastography (FibroScan) as part of routine clinical care\n* Age ≥ 18 years\n* Willing and able to provide signed informed consent\n\nExclusion Criteria:\n\n* Ascites (may interfere with liver stiffness measurement by either device) Body mass index (BMI) ≥ 35 kg\u002Fm² (may reduce measurement reliability of transient elastography)\n* Acute hepatitis or acute-on-chronic liver failure at the time of enrollment\n* History of liver transplantation\n* Hepatocellular carcinoma or other space-occupying liver lesions\n* Pregnant women\n* Skin lesions, infection, or scarring at the intended probe application site (right lobe of the liver, intercostal space)\n* Unable to cooperate with the measurement procedure (e.g., severe cognitive impairment)",{"count":419,"type":22},150,"Liver stiffness measurement is a key non-invasive tool for assessing liver fibrosis and cirrhosis in patients with chronic liver disease. Transient elastography (FibroScan) is currently the most widely used non-invasive reference standard, but it requires a dedicated device and trained operator, which may limit its accessibility in some clinical settings. This study aims to evaluate the diagnostic accuracy of a novel wearable patch-type ultrasound probe for detecting significant liver fibrosis and cirrhosis, using FibroScan as the reference standard. Patients with chronic liver disease will undergo simultaneous liver stiffness measurement using both the wearable patch ultrasound probe and FibroScan. The diagnostic performance of the patch probe, including sensitivity, specificity, and area under the receiver operating characteristic curve (AUC), will be evaluated against fibrosis staging determined by FibroScan, along with the correlation and agreement between the two measurement methods.",[422,26,152,423],"Liver Fibrosis","HEPATITIS B CHRONIC","2026-07-20",{"date":402,"type":36},{"date":296,"type":22},{"date":298,"type":22},{"name":429,"class":43},"Second Affiliated Hospital of Xi'an Jiaotong University",{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":434,"acronym":4,"eligibilityCriteria":435,"healthyVolunteers":436,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":437,"targetDuration":439,"studyType":23,"phases":4,"briefSummary":440,"conditions":441,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":449,"locationsCount":107},"100639822","a-prospective-cohort-study-on-the-epidemiological-investigation-diagnosis-and-treatment-of-hepatic-encephalopathy-100639822","NCT07612670","A Prospective Cohort Study on the Epidemiological Investigation, Diagnosis, and Treatment of Hepatic Encephalopathy","Inclusion Criteria:\n\n* For patients with liver cirrhosis and the general healthy population, the diagnosis of liver cirrhosis is made by doctors based on imaging, elastography, biopsy or clinical symptoms.\n* The patients themselves and their accompanying family members have smart phones, are proficient in using WeChat and mini-programs, and have a stable network environment.\n* They voluntarily sign the informed consent form, have good compliance, and fully understand this study.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years old;\n* Women planning to get pregnant, already pregnant or during lactation;\n* Incomplete relevant data information required;\n* Unable to proficiently use WeChat mini-program or unstable network environment;\n* Red-green color blindness or other irreparable visual impairments;\n* Heart, lung, or kidney failure or unstable vital signs;\n* Unwilling to participate in the study or unable to sign the informed consent form;\n* Any other situation that may interfere with the study assessment, increase the risk for the subjects, or affect their completion of the study, as judged by the researcher and deemed unsuitable for participating in this study;\n* Have participated in or are currently participating in other clinical trials within the past 3 months;",true,{"count":438,"type":22},700,"2 Years","Purpose Hepatic encephalopathy (HE) is a serious complication of liver cirrhosis that can cause memory loss, slow reaction, and even coma. In China, large-scale epidemiological data on HE are lacking, early diagnosis remains difficult, and treatment needs improvement. This study aims to investigate the prevalence of HE in Chinese liver disease patients and to explore better diagnostic methods and treatment strategies.\n\nDesign This is a prospective, multicenter cohort study led by Jiangsu Province Hospital, in collaboration with 7 other hospitals in Jiangsu Province. Between April 2026 and December 2029, the study plans to enroll over 700 patients with liver cirrhosis and 120 healthy volunteers.\n\nWhat participants will do Participants will use a WeChat mini-program to perform simple cognitive tests (e.g., reaction speed, attention) regularly. They will be followed up at month 1, 3, 6 after enrollment, and then every six months. The research team will collect routine laboratory results, medication records, and quality-of-life data.\n\nBenefits and risks Participants will receive closer health monitoring, which may help detect changes early. The study involves no additional drugs or invasive procedures, so risks are very low. All personal information will be kept strictly confidential and used only for medical research.\n\nVoluntary participation Participation is completely voluntary, and participants can withdraw at any time without affecting their routine medical care.",[442,443,26],"Hepatic Encephalopathy","Minimal Hepatic Encephalopathy","2026-07-14",{"date":406,"type":36},{"date":447,"type":22},"2026-08-01",{"date":134,"type":22},{"name":450,"class":43},"The First Affiliated Hospital with Nanjing Medical University",{"id":452,"slug":453,"hasResults":12,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":457,"eligibilityCriteria":458,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":459,"enrollmentInfo":460,"targetDuration":4,"studyType":54,"phases":462,"briefSummary":463,"conditions":464,"keywords":467,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":474,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":479,"locationsCount":481},"100578694","phase-3-role-of-nutritional-intervention-for-the-treatment-of-sarcopenia-in-cirrhotic-patients-with-refractory-ascites-candidate-to-transjugular-intrahepatic-portosystemic-shunt-placement-and-identification-of-prognostic-factors-related-to-clinical-outcome-100578694","NCT06814626","Role of Nutritional Intervention for the Treatment of Sarcopenia in Cirrhotic Patients With Refractory Ascites Candidate to Transjugular Intrahepatic Portosystemic Shunt Placement and Identification of Prognostic Factors Related to Clinical Outcome","Role of Nutritional Intervention With Friliver for the Treatment of Sarcopenia in Cirrhotic Patients With Refractory Ascites Candidate to Transjugular Intrahepatic Portosystemic Shunt Placement and Identification of Prognostic Factors Related to Clinical Outcome","NS-TIPS","Inclusion Criteria:\n\n* men and women with an age ≥ 18 and ≤ 80 years\n* clinical, radiological or histological diagnosis of liver cirrhosis\n* diagnosis of RA\n* confirmation of sarcopenia defined in CT scan as the sum of the psoas muscle areas measured at the level of the 3rd lumbar vertebra (PMA) ≤16 cm2\n* informed consent signed\n\nExclusion Criteria:\n\n* severe hepatic insufficiency (bilirubin\\> 5 mg\u002Fdl, MELD score\\> 18, Child-Pugh score\\> 9)\n* Congestive heart failure class ≥2 according to New York Heart Association criteria (NYHA)\n* Active coronary heart disease (myocardial infarction within 6 months of the study)\n* Severe pulmonary hypertension suspected on echocardiogram (systolic pulmonary arterial pressure \\[PAPs\\]\\> 35 mmHg) and confirmed with right cardiac catheterization (PAPs\\> 45mmHg)\n* Chronic renal failure (creatinine\\> 3 mg\u002Fdl)\n* Performance status ≥2 according to the Eastern Cooperative Oncology Group scale (ECOG)\n* History of grade III-IV hepatic encephalopathy or West Haven grade I-II hepatic encephalopathy episodes within the last 3 months\n* Uncontrolled systemic sepsis\n* Presence of Hepatocellular carcinoma\n* Complete portal vein thrombosis\n* Active bleeding from gastroesophageal varices. Patients with adequately treated gastroesophageal varices can be included in the study (banding ligation, sclerotherapy)\n* Diagnosis of extra hepatic neoplasia\n* Transplant recipients\n* Patients unable or unwilling to comply with the protocol requirements\n* Pregnant or lactating women\n* Patients unable to autonomously express their consent (incapable patients)\n* any other laboratory condition or result that in the opinion of the Principal Investigator, preclude the subject's participation in the study","80 Years",{"count":461,"type":22},72,[395],"The hypothesis is that in patients with cirrhosis and refractory ascites candidate to TIPS, and sarcopenia (identified by a PMA ≤16 cm² at the level of L3), who are at high-risk of 6-month mortality after TIPS placement, a post-TIPS 12 weeks nutritional intervention is associated with improved post-TIPS prognosis.\n\nThe primary objective is to evaluate the effect of a post-TIPS 12 weeks nutritional intervention on liver transplant-free six-month survival in sarcopenic candidates to TIPS for refractory ascites in cirrhosis.",[26,465,466],"Refractory Ascites in Patients With Cirrhosis","Sarcopenia in Liver Cirrhosis",[468,469,125,470,471,472],"nutritional treatment","sarcopenia","refractory ascites","transjugular intrahepatic portosystemic shunt placement","TIPS","2026-07-13",{"date":444,"type":36},{"date":476,"type":36},"2022-10-13",{"date":478,"type":22},"2027-12",{"name":480,"class":43},"The Mediterranean Institute for Transplantation and Advanced Specialized Therapies",2,{"id":483,"slug":484,"hasResults":12,"nctId":485,"briefTitle":486,"officialTitle":487,"acronym":488,"eligibilityCriteria":489,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":490,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":492,"conditions":493,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":503},"100454570","multi-analyte-blood-test-clinical-trial-100454570","NCT05199259","Multi-analyte Blood Test Clinical Trial","Collection of Blood to Evaluate Epigenomics and Protein Biomarkers for the Detection of Hepatocellular Carcinoma","LIVER-1","Inclusion Criteria:\n\n* Age 18 years or older.\n* Males and Females.\n* Having cirrhosis or meeting the AASLD guidelines for HCC\n* surveillance.\n* Clinically diagnosed with HCC or negative for HCC following disease\n* surveillance.\n* HCC positive Group: Subject has a recent (within 6 months of enrollment) clinically diagnosed, untreated hepatocellular carcinoma as defined by at least one ≥1 cm lesion exhibiting arterial phase hyperenhancement in combination with washout appearance and\u002For capsule by 4 phase CT scan or multiphase contrast enhanced MRI or biopsy is positive for HCC.\n* HCC negative Group: Non-cancer, at-risk subjects with chronic liver disease undergoing routine imaging surveillance for HCC, where the definitive lack of HCC within 3 months prior to enrollment has been verified by negative imaging, for HCC. No more than 200 subjects without cirrhosis can be enrolled in this group.\n* Sub-Group 1 (approximately 450 subjects) - negative by CT or MRI (No lesion, LR-1 or LR-2)\n* Sub-Group 2 (approximately 450 subjects) - negative by ultrasound\n\nExclusion Criteria:\n\n* Subjects that are unwilling or unable to sign the Informed Consent Form will be excluded.\n* Known cancer diagnosis of a cancer other than HCC within the past 5 years (with the exceptions of basal cell or squamous cell skin cancers).\n* Chemotherapy and\u002For radiation therapy within 5 years prior to enrollment\u002Fsample collection.\n* Prior or current treatment with sorafenib, regorafenib, or other treatment indicated for HCC.\n* Prior treatment with a DNA methyltransferase inhibitor such as with Vidaza (azacitidine) or Dacogen (decitabine)\n* Any HCC treatment prior to enrollment\u002Fblood sample collection (e.g., surgery, ablation, embolization, pharmacotherapy, radiotherapy, liver transplant or other treatment indicated for HCC).\n* IV contrast (e.g., CT and MRI) within 1 day \\[or 24 hours\\] of blood collection.\n* Less than 3 days between fine needle aspiration (FNA) of target pathology and blood collection.\n* Less than 7 days between biopsy (other than FNA) of target pathology and blood collection.\n* Any condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk.\n* For HCC negative subjects, patients with a prior diagnosis of HCC are also excluded.\n* Subjects that are pregnant will be exclude",{"count":491,"type":22},1200,"The objective of this study is the acquisition of whole blood samples and serum samples from participants with untreated Hepatocellular Carcinoma (HCC) and subjects undergoing Hepatocellular Carcinoma (HCC) surveillance. These samples will be used for research purposes to develop and validate the Helio multi-analyte blood test.",[26,189,188,183],"2026-07-09",{"date":496,"type":36},"2026-07-10",{"date":498,"type":36},"2022-03-01",{"date":500,"type":22},"2028-12",{"name":502,"class":68},"Helio Genomics",7,{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":508,"acronym":509,"eligibilityCriteria":510,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":511,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":512,"conditions":513,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":519,"startDateStruct":520,"completionDateStruct":522,"leadSponsor":524,"locationsCount":503},"100453229","collection-of-blood-from-healthy-patients-patients-with-benign-disease-and-patients-with-cancer-100453229","NCT05181826","Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer","ELITE","Inclusion Criteria:\n\n2.1.1 Age 18 years or older.\n\n2.1.2 A diagnosis of cancer, cancer remission, benign disease (benign tumor, diabetes, liver cirrhosis, chronic hepatitis B or hepatitis C virus infection, Chronic obstructive pulmonary disease, etc.) or apparently healthy volunteers. .\n\nExclusion Criteria:\n\n2.2.1 Patients that are unwilling or unable to sign the Informed Consent Form will be excluded.\n\n2.2.2 Approximately 50 mL of blood will be drawn from participants within an 8-week period under this protocol. Patients that have already given 50 mL of blood within this time frame will be excluded.",{"count":491,"type":22},"To acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select DNA methylation markers for the detection of various types of cancer, ii) identifying benign conditions that may induce false positive or false negative results, and iii) defining the effects of potential interfering substances, such as chemotherapy drugs.",[514,26,515,224,516,517,518],"Cancer","Chronic Hepatitis","Hepatitis C","Diabetes","COPD",{"date":496,"type":36},{"date":521,"type":36},"2019-05-21",{"date":523,"type":22},"2028-01",{"name":502,"class":68},{"id":526,"slug":527,"hasResults":12,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":4,"eligibilityCriteria":531,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":532,"targetDuration":534,"studyType":23,"phases":4,"briefSummary":535,"conditions":536,"keywords":538,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":543,"startDateStruct":545,"completionDateStruct":547,"leadSponsor":549,"locationsCount":107},"100641359","intraoperative-assessment-of-microcirculatory-function-using-vascular-occlusion-test-during-liver-transplantation-100641359","NCT07658794","Intraoperative Assessment of Microcirculatory Function Using Vascular Occlusion Test During Liver Transplantation","The Predictive Value of the Vascular Occlusion Test During Orthotopic Liver Transplantation for the Development of Early Allograft Dysfunction","Inclusion Criteria:\n\n* Adult patients aged 18 years or older\n* Patients scheduled to undergo orthotopic liver transplantation\n* Ability to obtain intraoperative Near-Infrared Spectroscopy measurements\n* Written informed consent obtained before enrollment\n\nExclusion Criteria:\n\n* Age younger than 18 years\n* Refusal or inability to provide informed consent\n* Emergency liver transplantation without sufficient time for enrollment\n* Inability to perform the Vascular Occlusion Test or obtain reliable NIRS measurements\n* Severe peripheral vascular disease or local upper-limb conditions interfering with monitoring",{"count":533,"type":22},50,"30 Days","Early allograft dysfunction (EAD) remains one of the most important complications following orthotopic liver transplantation (OLT). Currently, there is no established intraoperative biomarker that reliably predicts graft dysfunction at an early stage. Near-infrared spectroscopy (NIRS) combined with the vascular occlusion test (VOT) is a non-invasive method for assessing tissue oxygenation and microcirculatory reserve. This prospective observational study aims to investigate whether VOT-derived parameters, including desaturation slope, recovery slope and post-ischemic hyperemic area under the curve (AUC-H), can predict EAD in liver transplant recipients. Measurements will be performed at four predefined intraoperative timepoints: after induction of anesthesia, during the anhepatic phase, during the neohepatic phase and at the end of surgery. The primary outcome is the occurrence of EAD according to Olthoff criteria.",[26,537],"Early Allograft Dysfunction",[539,540,537,339,541],"Vascular Occlusion Test","Near-Infrared Spectroscopy","Microcirculation","2026-06-27",{"date":544,"type":36},"2026-07-01",{"date":546,"type":22},"2026-06",{"date":548,"type":22},"2027-06",{"name":550,"class":43},"Ippokrateio General Hospital of Thessaloniki",{"id":552,"slug":553,"hasResults":12,"nctId":554,"briefTitle":555,"officialTitle":556,"acronym":557,"eligibilityCriteria":558,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":559,"targetDuration":4,"studyType":54,"phases":561,"briefSummary":562,"conditions":563,"keywords":565,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":570,"startDateStruct":572,"completionDateStruct":574,"leadSponsor":576,"locationsCount":107},"100612423","comparison-of-underdilated-versus-standard-tips-in-preventing-variceal-rebleeding-in-patients-with-cirrhosis-100612423","NCT07253389","Comparison of Underdilated Versus Standard TIPS in Preventing Variceal Rebleeding in Patients With Cirrhosis","Comparison of Underdilated Versus Standard Transjugular Intrahepatic Portosystemic Shunt in Preventing Rebleeding From Esophagogastric Varices in Patients With Cirrhosis in Chinese Tertiary Hospitals: Protocol for a Multicenter Randomized Controlled Trial","UVR-TIPS","Inclusion Criteria:\n\n1\\. Age 18-75 years. 2. Diagnosis of liver cirrhosis according to the 2023 Consensus Opinion on the Clinical Diagnosis and Treatment of Liver Cirrhosis in China (Chinese Society of Gastroenterology). Diagnosis is based on clinical manifestations and imaging findings; histological confirmation is required if the diagnosis remains inconclusive.\n\n3\\. High-risk acute variceal bleeding, defined as any of the following:\n\n1. High-risk acute esophageal or type 1 gastroesophageal variceal bleeding, including: Child-Pugh grade B with a score \\> 7 and endoscopic evidence of active bleeding; Child-Pugh grade C with a score \\\u003C 14.\n2. Hepatic venous pressure gradient (HVPG) \\> 20 mmHg during bleeding.\n3. Early rebleeding within 5 days.\n4. Bleeding uncontrolled despite pharmacological and endoscopic therapy. 4. History of esophageal or gastric variceal bleeding with failure of standard first-line treatment \\[endoscopy combined with non-selective beta-blockers (NSBB)\\]; or first hemorrhage accompanied by grade 2 ascites and\u002For portal vein thrombosis; GOV2 or IGV1 gastric variceal bleeding; ectopic variceal bleeding; or bleeding from refractory portal hypertensive gastropathy.\n\n5\\. Planned TIPS procedure. 6. Ability and willingness to provide written informed consent.\n\nExclusion Criteria:\n\n1. Budd-Chiari syndrome or other causes of non-cirrhotic portal hypertension.\n2. Current or prior malignancy, including hepatocellular carcinoma or malignancies of other organs.\n3. Complete thrombosis of the main portal vein.\n4. Severe psychiatric or neurologic disorders (e.g., uncontrolled epilepsy, dementia).\n5. Prior liver resection or liver transplantation.\n6. Prior TIPS or surgical portosystemic shunt.\n7. Pregnancy or lactation.\n8. Any contraindication to TIPS, including:\n\n(1) Congestive heart failure (New York Heart Association class C or D, or left ventricular ejection fraction \\\u003C 50%).\n\n(2) Severe pulmonary hypertension (mean pulmonary artery pressure \\> 45 mmHg as measured invasively).\n\n(3) Uncontrolled systemic infection. (4) Severe overt hepatic encephalopathy (OHE) with unmodifiable spontaneous portosystemic shunt.\n\n9.Acute hemorrhage with a MELD score ≥ 30 and\u002For arterial lactate \\> 12 mmol\u002FL, or presence of acute-on-chronic liver failure (ACLF).\n\n10\\. Systemic conditions requiring ongoing glucocorticoid or nonsteroidal anti-inflammatory drug (NSAID) therapy.",{"count":560,"type":22},648,[119],"Transjugular intrahepatic portosystemic shunt (TIPS) is a key therapeutic intervention for complications of portal hypertension. However, the risk of post-procedural hepatic encephalopathy (HE) limits its broader clinical application. In the management of gastroesophageal variceal bleeding, the primary goal of TIPS is to reduce the portosystemic pressure gradient (PPG) to less than 12 mmHg (16 cmH₂O), which defines the standard TIPS procedure. The investigators hypothesize that, in patients undergoing TIPS for the prevention of variceal rebleeding, stent underdilation using a 6-mm balloon (underdilated TIPS) will not increase the risk of rebleeding but may reduce the incidence of overt HE and attenuate liver injury. To test this hypothesis, the investigators have designed a prospective, multicenter, randomized controlled trial.",[26,564],"Gastroesophageal Varices Bleeding",[26,566,567,568],"Esophageal and gastric variceal bleeding","Transjugular intrahepatic portosystemic shunt","Hepatic encephalopathy","2026-06-06",{"date":571,"type":36},"2026-06-09",{"date":573,"type":36},"2025-10-20",{"date":575,"type":22},"2029-09-30",{"name":577,"class":43},"Air Force Military Medical University, China",{"id":579,"slug":580,"hasResults":12,"nctId":581,"briefTitle":582,"officialTitle":583,"acronym":584,"eligibilityCriteria":585,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":586,"targetDuration":588,"studyType":23,"phases":4,"briefSummary":589,"conditions":590,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":594,"startDateStruct":596,"completionDateStruct":598,"leadSponsor":600,"locationsCount":602},"100640745","austrian-pbc-registry-100640745","NCT07598669","Austrian PBC Registry","Characterisation of Patients With Primary Biliary Cholangitis in Austria - A Prospective Registry and Biobank","PBC-AUT","Inclusion Criteria:\n\n* Age \\>18 years\n* Confirmed diagnosis of primary biliary cholangitis (at least two of the following three criteria must be fulfilled: persistent elevation of alkaline phosphatase above the upper limit of normal for at least 6 months; presence of antimitochondrial antibodies or PBC-specific antinuclear antibodies; characteristic histopathology)\n* Written informed consent for participation in the registry\n\nExclusion Criteria:\n\n* Withdrawal of written informed consent",{"count":587,"type":22},500,"10 Years","The goal of this registry is to better understand how primary biliary cholangitis develops over time, including the role of disease-related biomarkers, complications of the disease, and symptom burden. Patients with primary biliary cholangitis treated at participating centres in Austria will be invited to take part in this prospective registry. Participation in an associated biobank is optional. Clinical and laboratory data will be collected, and patients will be followed regularly through scheduled clinic visits. In addition, biological samples (serum, plasma, and, if available, liver tissue) may be collected and stored in the biobank for future research.",[591,26,592],"Primary Biliary Cholangitis","Portal Hypertension","2026-05-16",{"date":595,"type":36},"2026-05-20",{"date":597,"type":36},"2026-03-18",{"date":599,"type":22},"2040-12",{"name":601,"class":43},"Medical University of Vienna",11,{"id":604,"slug":605,"hasResults":12,"nctId":606,"briefTitle":607,"officialTitle":608,"acronym":609,"eligibilityCriteria":610,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":611,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":613,"conditions":614,"keywords":615,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":617,"lastUpdatePostDateStruct":618,"startDateStruct":620,"completionDateStruct":622,"leadSponsor":624,"locationsCount":107},"100630648","long-term-efficacy-and-safety-of-lsd-versus-tips-for-cirrhotic-portal-hypertension-bleeding-and-hypersplenism-100630648","NCT07490405","Long-term Efficacy and Safety of LSD Versus TIPS for Cirrhotic Portal Hypertension Bleeding and Hypersplenism","Long-term Efficacy and Safety of Laparoscopic Splenectomy and Azygoportal Disconnection Versus Transjugular Intrahepatic Portosystemic Shunt for Cirrhotic Portal Hypertension With Acute Esophagogastric Variceal Bleeding and Hypersplenism","LSD、TIPS","Inclusion Criteria:\n\n1. Confirmed diagnosis of cirrhotic portal hypertension.\n2. Endoscopic examination confirmed the presence of severe esophagogastric varices accompanied by acute bleeding. Rebleeding occurred after endoscopic variceal ligation (EVL) treatment..\n3. Presence of hypersplenism causing significant thrombocytopenia and\u002For leukopenia.\n4. Liver function Child-Pugh class A or B (score 7-9).\n5. Age 18-75 years.\n6. Patient provides written informed consent.\n\nExclusion Criteria:\n\n1. Liver function Child-Pugh class C (score ≥10), or Model for End-Stage Liver Disease (MELD) score \\>18.\n2. Severe right heart failure or pulmonary hypertension.\n3. Uncontrolled systemic infection or sepsis.\n4. Polycystic liver disease, portal cavernous transformation, or portal vein thrombosis (affecting procedure or shunt creation).\n5. Advanced hepatocellular carcinoma (beyond Milan criteria) or other uncontrolled malignancies.\n6. Severe hepatic encephalopathy (West-Haven grade III-IV) unresponsive to medication.\n7. Severe contrast agent allergy (affecting TIPS procedure).\n8. Pregnancy or lactation.\n9. Any severe non-hepatic disease with a life expectancy \\\u003C1 year.\n10. Recent gastric and duodenal ulcers.\n11. Inability to comply with follow-up or provide informed consent.",{"count":612,"type":22},140,"This study aims to compare two treatments for cirrhotic portal hypertension with acute esophagogastric variceal bleeding and hypersplenism: laparoscopic splenectomy and azygoportal disconnection (LSD) and transjugular intrahepatic portosystemic shunt (TIPS). It is a single-center, prospective trial. The primary outcome is the incidence of post-procedure hepatic encephalopathy. Secondary outcomes include changes in hepatic venous pressure gradient, portal and hepatic artery hemodynamics, liver function, renal function, complete blood count, immune function, hepatic reserve capacity, serological markers of liver fibrosis, re-bleeding rate, hepatocellular carcinoma incidence, recompensation incidence, overall survival, and bleeding-free survival. The study will provide high-level evidence for optimal treatment selection in this patient population.",[26],[26,616,472],"LSD","2026-05-14",{"date":619,"type":36},"2026-05-18",{"date":621,"type":22},"2026-06-01",{"date":623,"type":22},"2036-04-01",{"name":625,"class":43},"Northern Jiangsu People's Hospital",{"id":627,"slug":628,"hasResults":12,"nctId":629,"briefTitle":630,"officialTitle":631,"acronym":4,"eligibilityCriteria":632,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":459,"enrollmentInfo":633,"targetDuration":4,"studyType":54,"phases":635,"briefSummary":636,"conditions":637,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":638,"lastUpdatePostDateStruct":639,"startDateStruct":641,"completionDateStruct":643,"leadSponsor":645,"locationsCount":107},"100640330","sonazoid-ceus-for-early-hcc-surveillance-100640330","NCT07590284","Sonazoid CEUS for Early HCC Surveillance","A Multicenter, Prospective Study of Sonazoid CEUS for Early HCC Surveillance in a High-risk Population","Inclusion Criteria:\n\n1. Cirrhotic patients diagnosed clinically or radiologically due to any etiology (patients with cirrhosis due to congenital fibrosis and patients with cirrhosis due to vascular causes were excluded).\n2. Age 18-80 years old.\n3. Able to receive regular imaging, including US, CEUS, and CECT or CEMRI or EOB-MRI, according to the diagnostic and treatment procedures.\n4. Obtained informed consent from the patient.\n\nExclusion Criteria:\n\n1. Patients with pathologic or enhanced imaging of established HCC who have not undergone curative treatment.\n2. Patients with known hypersensitivity to enhanced imaging contrast agents.\n3. Patients with severe cardiac, pulmonary or renal insufficiency that precludes CECT or CEMRI or EOB-MRI.\n4. Lactating and pregnant women.\n5. Those who are not suitable for enrollment as assessed by the investigator.\n6. Patients with egg or egg-product allergy, or with severe right-to-left cardiac shunt or intrapulmonary shunt.",{"count":634,"type":22},556,[119],"This study is a multicenter, prospective study. In this study, enrolled subjects are cirrhotic patients of any etiology. The US and Sonazoid CEUS monitoring strategy was performed for cirrhotic patients: US and AFP joint with Sonazoid CEUS every 4 to 6 months, and combined CECT\u002FCEMRI every 12 months.",[26,422],"2026-05-11",{"date":640,"type":36},"2026-05-15",{"date":642,"type":22},"2026-05-30",{"date":644,"type":22},"2029-12-30",{"name":646,"class":43},"Tianjin Third Central Hospital",{"id":648,"slug":649,"hasResults":12,"nctId":650,"briefTitle":651,"officialTitle":652,"acronym":653,"eligibilityCriteria":654,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":655,"targetDuration":4,"studyType":54,"phases":657,"briefSummary":658,"conditions":659,"keywords":661,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":667,"lastUpdatePostDateStruct":668,"startDateStruct":669,"completionDateStruct":670,"leadSponsor":672,"locationsCount":301},"100639849","underdilated-vcx-tips-versus-evl-plus-nsbb-for-secondary-prophylaxis-of-variceal-bleeding-in-cirrhosis-100639849","NCT07587671","Underdilated VCX-TIPS Versus EVL Plus NSBB for Secondary Prophylaxis of Variceal Bleeding in Cirrhosis","Underdilated VIATORR Controlled Expansion Transjugular Intrahepatic Portosystemic Shunt Versus Endoscopic Variceal Ligation Plus Nonselective Beta-Blockers for Secondary Prophylaxis of Variceal Bleeding in Patients With Cirrhosis: A Multicenter, Open-Label, Randomized Controlled Trial","U-TIPS","Inclusion Criteria:\n\n* Age 18 to 75 years, regardless of sex.\n* Diagnosis of liver cirrhosis based on previous histology, imaging, laboratory tests, and\u002For clinical manifestations.\n* Hospitalization for acute upper gastrointestinal bleeding, with endoscopic confirmation that the bleeding is related to esophageal varices or type 1 gastroesophageal varices.\n* Successful control of acute bleeding after standard acute-phase treatment, with stable vital signs and entry into the secondary prophylaxis phase.\n* Child-Pugh score of 5 to 13.\n* The investigator judges that both underdilated VCX-TIPS and EVL plus NSBB are clinically feasible and that randomization is appropriate.\n* The participant or legally authorized representative understands the study procedures and voluntarily signs written informed consent.\n\nExclusion Criteria:\n\n* Hemodynamic instability, persistent active bleeding, or need for immediate rescue TIPS, surgical hemostasis, or interventional radiologic hemostasis.\n* A strong current indication for early or pre-emptive TIPS that makes randomization to EVL plus NSBB clinically inappropriate.\n* Child-Pugh score greater than 13.\n* Previous TIPS, surgical portosystemic shunt, BRTO, CARTO, PARTO, or other procedures that substantially alter portosystemic blood flow.\n* Isolated gastric varices, type 2 gastroesophageal varices, ectopic varices, or a bleeding source other than esophageal varices or type 1 gastroesophageal varices.\n* Non-cirrhotic portal hypertension.\n* Cavernous transformation of the portal vein or portal venous thrombosis that makes standardized TIPS technically infeasible.\n* Previous recurrent or refractory overt hepatic encephalopathy, or a history of West Haven grade II to IV overt hepatic encephalopathy unrelated to gastrointestinal bleeding.\n* Severe heart failure, severe pulmonary hypertension, severe tricuspid regurgitation, right heart failure, or other contraindications to TIPS.\n* Uncontrolled severe infection, sepsis, or multiple organ failure.\n* Hepatocellular carcinoma beyond the Milan criteria or other advanced malignancy.\n* Severe renal insufficiency requiring long-term renal replacement therapy.\n* Pregnancy or breastfeeding.\n* Absolute contraindication to EVL, NSBB, or TIPS.\n* Any condition that, in the investigator's judgment, makes the participant unsuitable for the study or unable to complete follow-up.",{"count":656,"type":22},240,[119],"Variceal bleeding is a major complication of portal hypertension in patients with cirrhosis and is associated with substantial risks of rebleeding and death. Current guidelines recommend endoscopic variceal ligation combined with nonselective beta-blockers as standard secondary prophylaxis for esophageal variceal bleeding and type 1 gastroesophageal variceal bleeding. Transjugular intrahepatic portosystemic shunt can markedly reduce portal pressure and prevent recurrent variceal bleeding, but its broader use in secondary prophylaxis is limited by the risk of post-TIPS hepatic encephalopathy and liver function deterioration.\n\nThe VIATORR Controlled Expansion stent is designed to allow controlled expansion between 8 and 10 mm. However, even 8-mm TIPS may still be associated with a substantial risk of overt hepatic encephalopathy. This trial evaluates an underdilated VCX-TIPS strategy, in which a commercially available 8-10 mm VIATORR Controlled Expansion stent is initially dilated only with a 6-mm balloon, aiming to achieve sufficient portal decompression while reducing the risk of excessive shunting.\n\nThis is a prospective, multicenter, open-label, parallel-group, randomized superiority trial. Eligible patients with cirrhosis who have recovered from acute esophageal variceal bleeding or type 1 gastroesophageal variceal bleeding and have entered the secondary prophylaxis phase will be randomly assigned in a 1:1 ratio to receive either underdilated VCX-TIPS or endoscopic variceal ligation plus nonselective beta-blockers. The primary outcome is the composite of all-cause death or clinically significant upper gastrointestinal rebleeding within 1 year after randomization.",[26,592,564,660,442],"Esophageal Varices",[254,662,663,664,567,665,666,568],"Portal hypertension","Esophageal variceal bleeding","Secondary prophylaxis","Underdilation","Endoscopic variceal ligation","2026-05-07",{"date":617,"type":36},{"date":447,"type":22},{"date":671,"type":22},"2030-07-30",{"name":673,"class":43},"West China Hospital",{"id":675,"slug":676,"hasResults":12,"nctId":677,"briefTitle":678,"officialTitle":679,"acronym":4,"eligibilityCriteria":680,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":681,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":683,"conditions":684,"keywords":689,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":694,"lastUpdatePostDateStruct":695,"startDateStruct":697,"completionDateStruct":699,"leadSponsor":701,"locationsCount":4},"100636914","ultrasound-prediction-of-esophageal-variceal-bleeding-risk-100636914","NCT07571876","Ultrasound Prediction of Esophageal Variceal Bleeding Risk","Splenic Size and Portal Vein Diameter on Ultrasound in Predicting Esophageal Variceal Bleeding Risk","Inclusion Criteria:\n\n* Adult patients (age ≥18 years) with chronic liver disease and clinical\u002Flaboratory\u002Fradiological evidence of liver cirrhosis\n* Both compensated and decompensated cirrhosis (Child-Pugh classes A, B, and C)\n* Patients scheduled for upper gastrointestinal endoscopy\n* Patients who provide informed consent\n\nExclusion Criteria:\n\n* Previous history of endoscopic variceal band ligation or sclerotherapy\n* Prior surgical portosystemic shunt procedures or transjugular intrahepatic portosystemic shunt (TIPS)\n* Hepatocellular carcinoma with portal vein thrombosis\n* Previous splenectomy\n* Patients receiving beta-blockers for variceal bleeding prophylaxis\n* Poor quality ultrasound images due to obesity or ascites\n* Refusal to participate in the study",{"count":682,"type":22},165,"This prospective observational study aims to evaluate the accuracy of using routine abdominal ultrasound to predict the risk of esophageal variceal bleeding in adult patients with liver cirrhosis. Esophageal variceal bleeding is a serious complication of chronic liver disease. While upper gastrointestinal endoscopy is the current standard for diagnosing and grading these varices, it is an invasive procedure.\n\nIn this study, researchers will use ultrasound to measure the patient's spleen size and portal vein diameter. These non-invasive measurements will then be compared to the results of a standard upper endoscopy performed within 48 to 72 hours. The goal is to determine if these simple ultrasound measurements can reliably predict the presence, grade, and bleeding risk of esophageal varices, which could potentially reduce the need for routine invasive endoscopic screenings in the future.",[685,686,687,660,26,592,688],"Variceal Bleeding","Ultrasonography","Esophageal Bleeding","Chronic Liver Disease (CLD)",[690,691,692,693],"portal vein diameter","splenic size","ultrasound","esophageal variceal bleeding risk","2026-05-04",{"date":696,"type":36},"2026-05-06",{"date":698,"type":22},"2026-04",{"date":700,"type":22},"2027-05",{"name":42,"class":43}]